Bariatric and Metabolic Institute, M61, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44195, USA.
Department of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Obes Surg. 2019 Apr;29(4):1122-1129. doi: 10.1007/s11695-018-3570-8.
There is limited data in the literature evaluating outcomes of bariatric surgery in severely obese patients with left ventricular assist device (LVAD) as a bridge to make them acceptable candidates for heart transplantation. This study aims to assess the safety and effectiveness of laparoscopic sleeve gastrectomy (LSG) in patients with previously implanted LVAD at our institution.
All the patients with end-stage heart failure (ESHF) and implanted LVAD who underwent LSG from2013 to January 2017 were studied.
Seven patients with end stage heart failure (ESHF) and implanted LVAD were included. The median age and median preoperative BMI were 39 years (range: 26-62) and 43.6 kg/m (range 36.7-56.7), respectively. The median interval between LVAD implantation and LSG was 38 months (range 15-48). The median length of hospital stay was 9 days (rang: 6-23) out of which 4 patients had planned postoperative ICU admission. Thirty-day complications were noted in 5 patients (3 major and 2 minor) without any perioperative mortality. The median duration of follow-up was 24 months (range 2-30). At the last available follow-up, the median BMI, %EWL, and %TWL were 37 kg/m, 47%, and 16%, respectively. The median LVEF before LSG and at the last follow-up point (before heart transplant) was 19% (range 15-20) and 22% (range, 16-35), respectively. In addition, the median NYHA class improved from 3 to 2 after LSG. Three patients underwent successful heart transplantations.
Patients with morbid obesity, ESHF, and implanted LVAD constitute a high-risk cohort. Our results with 7 patients and result from other studies (19 patients) suggested that bariatric surgery may be a reasonable option for LVAD patients with severe obesity. Bariatric surgery appears to provide significant weight loss in these patients and may improve candidacy for heart transplantation.
在文献中,关于肥胖症患者接受减重手术(LSG)以成为接受心脏移植的可接受候选人的结果评估,数据十分有限。本研究旨在评估我院先前植入左心室辅助装置(LVAD)的患者行腹腔镜袖状胃切除术(LSG)的安全性和有效性。
研究纳入了 2013 年至 2017 年 1 月期间因终末期心力衰竭(ESHF)和植入 LVAD 而行 LSG 的所有患者。
7 例终末期心力衰竭(ESHF)和植入 LVAD 的患者被纳入研究。中位年龄和术前 BMI 分别为 39 岁(范围:26-62 岁)和 43.6kg/m(范围 36.7-56.7)。LVAD 植入与 LSG 之间的中位间隔为 38 个月(范围 15-48 个月)。中位住院时间为 9 天(范围 6-23 天),其中 4 例患者计划术后入住 ICU。5 例患者出现 30 天并发症(3 例主要并发症和 2 例次要并发症),无围手术期死亡。中位随访时间为 24 个月(范围 2-30 个月)。最后一次随访时,中位 BMI、%EWL 和 %TWL 分别为 37kg/m、47%和 16%。LSG 前和最后随访点(心脏移植前)的中位 LVEF 分别为 19%(范围 15-20)和 22%(范围 16-35)。此外,LSG 后 NYHA 分级中位数从 3 级改善至 2 级。3 例患者成功进行了心脏移植。
肥胖症、ESHF 和植入 LVAD 的患者构成了高风险人群。我们的研究结果(共 7 例患者)以及其他研究(19 例患者)表明,减重手术可能是严重肥胖 LVAD 患者的合理选择。减重手术似乎为这些患者提供了显著的体重减轻,并可能提高心脏移植的候选资格。